Advertisement
Advertisement
U.S. Markets open in 1 min
Advertisement
Advertisement
Advertisement
Advertisement

Werewolf Therapeutics, Inc. (HOWL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.53+1.50 (+10.69%)
At close: 04:00PM EST
15.53 0.00 (0.00%)
Pre-Market: 08:25AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.03
Open15.25
Bid13.25 x 800
Ask0.00 x 1100
Day's Range14.61 - 15.88
52 Week Range11.23 - 23.99
Volume180,476
Avg. Volume41,888
Market Cap429.853M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.50
  • GlobeNewswire

    Werewolf Therapeutics to Present Preclinical Data on INDUKINE™ Molecules at the 63rd American Society of Hematology (ASH) Annual Meeting

    Data demonstrates the strength of Werewolf’s innovative therapeutic approach across multiple conditionally activated pipeline programsCAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the Company will present preclinical da

  • GlobeNewswire

    Werewolf Therapeutics Reports Third Quarter 2021 Financial Results and Business Update

    -Clinical Trial Collaboration with Merck for WTX-124 INDUKINE Program- -On Track to File Two INDs in First Half of 2022- CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for

  • GlobeNewswire

    Werewolf Therapeutics to Present at Upcoming Conferences in November 2021

    CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference on Thursday, November 18th at 3:00am EST Evercore ISI HealthCONx Conference on Tuesday, November

Advertisement
Advertisement